US Stocks: Apellis shares double on Biogen’s $5.6 billion buyout plan by ET Markets | March 31, 2026 9:05 pm | Indian Stocks, Market, News Biogen will buy Apellis Pharmaceuticals for about $5.6 billion, adding a promising kidney disease drug to broaden its rare-disease portfolio amid efforts to diversify beyond its slowing multiple sclerosis franchise.
